Journal
NANOMEDICINE
Volume 15, Issue 7, Pages 725-743Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2019-0316
Keywords
Alzheimer's disease; contrast agents; diagnosis; MRI; nanoparticles
Funding
- Australian Postgraduate Award PhD scholarship
- Australian Research Council Discovery Early Career Award [DE170100628]
- Australian Research Council Linkage grant [LP150101014]
- Yulgibar/Dementia Australia
Ask authors/readers for more resources
Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer's disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: 'Alzheimer's disease' AND 'nanoparticles' AND 'Magnetic Resonance Imaging.' 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available